Lexeo Therapeutics, INC

Lexeo Therapeutics has finalized its acquisition of Mantle Therapeutics, integrating its pipeline and expanding its therapeutic focus.

Lexeo Therapeutics announced its definitive agreement to acquire Mantle Therapeutics, bolstering its Friedreich Ataxia (FA) pipeline with multiple new therapeutic modalities and strategic collaborations.

Lexeo Therapeutics announced key business highlights and financial results for Q2 2026, including the initiation of a pivotal trial for LX2006 and FDA RMAT designation for LX2020, with cash runway extending into 2028.

Lexeo Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class III Directors and the ratification of KPMG LLP as its independent auditor.

Lexeo Therapeutics announces finalized pivotal trial protocol for LX2006, targeting Friedreich Ataxia cardiomyopathy with a potential Biologics License Application submission in 2028.

Lexeo Therapeutics reported Q1 2026 business highlights and financial results, noting progress in its cardiac genetic medicine pipeline and a cash runway into 2028.

Lexeo Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing clinical trial progress and financial performance, including a net loss of $25.9 million.

Lexeo Therapeutics reported its first-quarter 2026 financial results, highlighting progress in its gene therapy pipeline for cardiovascular diseases and a strong cash position.

Lexeo Therapeutics reports Q3 2025 financial results with increased net losses but significant clinical progress for LX2006 and a substantial post-period capital raise.

Lexeo Therapeutics reported significant clinical progress for its lead gene therapy candidates and bolstered its financial position with a $73.1 million private placement, extending its cash runway into 2028.

Lexeo Therapeutics files an amendment to its Q1 2025 quarterly report to correct language in exhibits related to internal control over financial reporting.

Lexeo Therapeutics announces Q1 2025 financial results, highlighting progress in clinical trials for LX2006 and LX2020, and a strategic capital reallocation.

Lexeo Therapeutics highlights advancements in its gene therapy pipeline targeting cardiovascular and neurodegenerative diseases, including positive clinical data updates and regulatory alignment for its lead candidates.

Lexeo Therapeutics outlines its capital stock structure, including common and preferred stock details, voting rights, dividend policies, and anti-takeover provisions in its recent 10-K filing.

Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc., received 54,750 shares of common stock on September 24, 2026.

Narinder Pal Bhalla, Chief Medical Officer of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.

Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.

Richard Nolan Townsend, Chief Executive Officer and a Director of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.

Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc., sold 4,117 shares of common stock on August 18, 2026 for $4.91 per share.

Richard Nolan Townsend, Chief Executive Officer and a Director of Lexeo Therapeutics, Inc., sold 3,345 shares of common stock on August 18, 2026 for $4.95 per share.

Lexeo Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors and ratify auditors.

Lexeo Therapeutics, Inc. has filed a proxy statement supplement detailing an amendment to its non-employee director compensation policy, increasing equity awards for eligible directors.

LEXEO Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 26, 2025, outlining key proposals for voting.

Lexeo Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 26, 2025, featuring proposals for director elections and ratification of the independent accounting firm.

Lexeo Therapeutics has scheduled its annual stockholder meeting for June 25, 2024, with proposals including the election of a Class I director and ratification of KPMG LLP as the independent auditor.

Lexeo Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 25, 2024, featuring proposals for director election and auditor ratification.

Lexeo Therapeutics is registering for the resale of up to 6,974,248 shares of its common stock by selling stockholders after a recent private placement.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, reporting beneficial ownership of 4.1% and 1.0% respectively in Lexeo Therapeutics, Inc.

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 5.3% of Lexeo Therapeutics, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and its affiliates have reported beneficial ownership of 9.99% of Lexeo Therapeutics, Inc. common stock, totaling 7,844,311 shares.

State Street Corporation has disclosed a beneficial ownership of 5.5% in Lexeo Therapeutics Inc. as of June 30, 2026.

Paradigm BioCapital Advisors and affiliates have reported an 8.3% beneficial ownership stake in Lexeo Therapeutics, Inc.

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership of 9.69% in Lexeo Therapeutics, Inc. common stock as of March 31, 2026.